Fagron Q3 revenue rises 6.4% to €228 mln as FDA clears Wichita expansion
PositiveFinancial Markets

Fagron has reported a 6.4% increase in its Q3 revenue, reaching €228 million, a positive sign for the pharmaceutical company. This growth comes alongside the FDA's approval for the expansion of its Wichita facility, which is expected to enhance production capabilities and meet rising demand. This expansion not only reflects Fagron's commitment to growth but also positions the company favorably in the competitive pharmaceutical market.
— Curated by the World Pulse Now AI Editorial System